

## Ccl11

## Recombinant Rat Eotaxin

<b>Catalog No.</b>	CS285A CS285B CS285C	<b>Quantity:</b>	5 µg 20 µg 1 mg
<b>Alternate Names:</b>	C-C motif chemokine 11, Eosinophil chemotactic protein, Eotaxin, Small inducible cytokine A11, Small inducible cytokine subfamily A11, Small-inducible cytokine A11		
<b>Description:</b>	Eotaxin/CCL11 is a potent eosinophil chemoattractant that was originally purified from bronchoalveolar lavage fluid of guinea pigs sensitized by aerosol challenge with ovalbumin. Human CCL11 cDNA encodes a 97 amino acid residue precursor protein from which the aminoterminal 23 amino acid residues are cleaved to generate the 74 amino acid residue mature human CCL11. At the protein sequence level, mature human CCL11 is approximately 60% identical to mature mouse and guinea pig CCL11. Human CCL11 is chemotactic for eosinophils, but not mononuclear cells or neutrophils. The CC chemokine receptor 3 (CCR3) has now been identified to be a specific human CCL11 receptor. CCR3 has also been shown to serve as a cofactor for a restricted subset of primary HIV viruses and binding of CCL11 to CCR3 inhibited infection by the HIV isolates.		
<b>Physical Appearance:</b>	Sterile Filtered White lyophilized (freeze-dried) powder.		
<b>Gene ID:</b>	29397		
<b>Source:</b>	<i>E. coli</i>		
<b>Molecular Weight:</b>	Approximately 8.4 kDa, a single non-glycosylated polypeptide chain containing 74 amino acids.		
<b>Formulation:</b>	Lyophilized from a 0.2 µm filtered concentrated solution in 20 mM PB, pH 7.4 + 150 mM NaCl.		
<b>Purity:</b>	>95% by SDS-PAGE and HPLC analyses.		
<b>Endotoxin Level:</b>	Less than 1EU/µg of Recombinat Rat Eotaxin as determined by LAL method.		
<b>Biological Activity:</b>	Data is not available.		
<b>Amino Acid Sequence:</b>	HPGSIPTSCC FTMTSKKIPN TLLKSYKRIT NNRCTLKAIV FKTKLGKEIC ADPKKKWVQD ATKHLDQKLQ TPKP		
<b>Reconstitution:</b>	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤-20°C. Further dilutions should be made in appropriate buffered solutions.		
<b>Storage &amp; Stability:</b>	This lyophilized preparation is stable at 2-4°C, but should be kept desiccated at -20°C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2 -4°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -80°C. <b>Avoid repeated freeze/thaw cycles.</b>		

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

